treatment of postherpetic neuralgia

Extracorporeal shockwave therapy versus placebo for truncal postherpetic neuralgia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410602130466

Enrollment

Registered

2024-10-17

Start date

2024-07-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases Skin and Connective Tissue Diseases

Interventions

Extracorporeal shockwave therapy

ESWT placebo program

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1- males and females 2- 50-65 age 3- pain duration is more than 18 months after viral infection 4- body mass index less than or equal to 25 5- medication they are taking are gabapentin g/d and pregabalin mg/d

Exclusion criteria

Exclusion criteria: 1- patients whose are suffering from cancer and chronic inflammatory diseases 2- patients those are receiving steroid and/or immunosuppressant 3- patients with thoracic disc lesion at any level 4- diabetic patients 5- all patient do not received ESWT before 6- arthritis patients 7- patients of history of allergy to coupling agent 8- liver or kidney dysfunction 9- thrombosis or abnormal coagulation 10- cardiac pacemaker 11- pregnant 12- mental disorders.

Design outcomes

Primary

Measure	Time frame
post-herpetic neuralgia	—

Secondary

Measure	Time frame
insomnia	—

Countries

Egypt

Contacts

Public ContactAmal youssef

lecturer of physical therapy for pediatric at faculty of physical therapy Pharos University

amal.youssef@pua.edu.eg+201002472964

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026